비소세포폐암 환자에서 수술 후 동시항암화학요법과 순차적 방사선화학요법의 비교연구
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 오영택 | - |
dc.contributor.author | 김환익 | - |
dc.date.accessioned | 2019-10-21T07:30:40Z | - |
dc.date.available | 2019-10-21T07:30:40Z | - |
dc.date.issued | 2017-08 | - |
dc.identifier.other | 25795 | - |
dc.identifier.uri | https://dspace.ajou.ac.kr/handle/2018.oak/19085 | - |
dc.description | 학위논문(석사)--아주대학교 일반대학원 :의학과,2017. 8 | - |
dc.description.tableofcontents | Ⅰ. Introduction 1 Ⅱ. Methods and Materials 3 Ⅲ. Results 6 Ⅳ. Discussion 14 Ⅴ. References 18 국문초록 23 | - |
dc.language.iso | eng | - |
dc.publisher | The Graduate School, Ajou University | - |
dc.rights | 아주대학교 논문은 저작권에 의해 보호받습니다. | - |
dc.title | 비소세포폐암 환자에서 수술 후 동시항암화학요법과 순차적 방사선화학요법의 비교연구 | - |
dc.title.alternative | Comparison of concurrent chemoradiotherapy versus sequential radiochemotherapy in patients with completely resected non-small cell lung cancer | - |
dc.type | Thesis | - |
dc.contributor.affiliation | 아주대학교 일반대학원 | - |
dc.contributor.alternativeName | Hwanik Kim | - |
dc.contributor.department | 일반대학원 의학과 | - |
dc.date.awarded | 2017. 8 | - |
dc.description.degree | Master | - |
dc.identifier.localId | 788626 | - |
dc.identifier.url | http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000025795 | - |
dc.subject.keyword | 비소세포폐암 | - |
dc.subject.keyword | 동시항암화학요법 | - |
dc.subject.keyword | 순차적 방사선화학요법 | - |
dc.description.alternativeAbstract | Purpose: Our institution has executed two different kinds of adjuvant protocols in treating patients with non-small cell lung cancer (NSCLC): 1) chemotherapy followed by concurrent chemoradiotherapy (CTx-CCRT) and 2) sequential postoperative radiotherapy (PORT) followed by postoperative chemotherapy (POCT) (i.e. RT-CT). This study is targeted to compare the clinical outcomes between the two adjuvant protocols. Materials and Methods: From March 1997 to October 2012, 68 patients were treated with CTx-CCRT (n = 25) and RT-CT (n = 43). The CTx-CCRT protocol consisted of 2 cycles of cisplatin-based POCT followed by PORT concurrently with 2 cycles of POCT. The RT-CT protocol consisted of PORT followed by 4 cycles of cisplatin-based POCT. PORT was implemented with conventional fractionations of 50.4 – 60 Gy dose. We compared the outcomes between the two adjuvant protocols and studied about the clinical factors affecting survivals. Results: Median follow-up time was 43.9 months (range 3.2 – 74.0), and the 5-year overall survival (OS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were 53.9%, 68.2%, and 51.0%, respectively. There were no significant differences in OS (p = 0.074), LRFS (p = 0.094), and DMFS (p = 0.490) between the two protocols. In multivariable analyses, adjuvant protocol remained as a significant prognostic factor for LRFS, favouring CTx-CCRT (HR = 3.506, p = 0.046) over RT-CT, not for OS (HR = 0.647, p = 0.229). Conclusions: CTx-CCRT protocol increased LRFS more than RT-CT protocol in patients with completely resected NSCLC, but not in OS. Further studies are warranted to evaluate the benefit of CTx-CCRT strategy compared with sequential strategy. | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.